Join the Quest
We are building our Medical Advisory Board and we are looking to collaborate with Physicians, Psychiatrists & Healthcare Practitioners.
Advisor Shared Values and Expertise:
- Shared passion to make a real difference in quality of life
- Scientific knowledge and expertise in cannabinoid-based medicine
CanaQuest is a clinical-stage life sciences company developing innovative cannabinoid-based therapeutics. Our primary focus, CQ-001, combines cannabidiol (CBD) with Omega-3 fatty acids to treat refractory epilepsy in 30%-40% of the 65 million affected people worldwide. This drug enhances binding to critical PPAR receptors in the brain, showing a 35% increase in potency over isolated CBD in pre-clinical models. Our expertise with FDA-approved cannabidiol (Epidiolex®) positions us at the forefront of epilepsy treatment innovation.
Mission Objective:
Our goal is to treat 30%-40% of the 65 million people worldwide who suffer from refractory epilepsy, which is not effectively treatable with current anti-epileptic drugs, excluding CBD-based medications.
Value Proposition:
CQ-001 leverages the synergistic effects of CBD and Omega-3s to enhance binding to critical PPAR receptors in the brain. This synergy has demonstrated a 35% increase in potency compared to isolated CBD in pre-clinical epilepsy models.
Drug Candidate – CQ-001: CQ-001 has the potential to offer superior benefits compared to existing treatments like Epidiolex® at lower dosages and with reduced side effects. The drug aims to treat neurological conditions such as epilepsy, PTSD, and anxiety. CanaQuest’s advanced research and promising pre-clinical results position it as a leader in next-generation cannabinoid therapies, presenting a compelling investment opportunity.
Pre-Clinical Trials: Pre-clinical trials on rodents were successfully completed at Western University. A pre-clinical MES model of epilepsy conducted on mice at the Ontario Brain Institute revealed that CQ-001 demonstrated a 35% increase in potency compared to isolated cannabidiol alone. This indicates that the drug is significantly more effective at protecting against seizure activity.
Synergistic Effect: The combination of cannabidiol and the proprietary API composition in CQ-001 demonstrated potentiation, resulting in an effect greater than the sum of the individual effects of cannabidiol or the proprietary API alone. This suggests the potential for using lower dosages to achieve similar efficacy, potentially translating to a safer side effect profile.
Accumulated Expertise: To commercialize and obtain relevant regulatory approvals for CQ-001, CanaQuest has gathered a strong team of consultants and advisors with extensive experience in cannabinoid therapeutics, including:
-
-
- Acting Chief Scientific Officer – Dr. Jordyn Stuart, Ph.D., BS, BS: With 12 years of pre-clinical cannabinoid research experience, including 6 years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma), Dr. Stuart has been involved in the launch of Epidiolex®.
- Chairman of Advisory Board – Dr. Paul Dick, DVM, MSc: With over 30 years of experience in the pharmaceutical and animal health industries, Dr. Dick has served on several boards, including the Animal Health Institute and the Ontario Veterinary Medical Association.
- Interim Chief Operating Officer – Eddie Francis, MS: With a background in Molecular Biology and Oncology, Eddie has over 10 years of experience in the natural therapeutic sector and 20 years in the private sector, focusing on mental health and wellness initiatives.
-
We have also secured ongoing relationships with trusted legal, regulatory, and compliance advisors who will help move our business forward.
Regulatory Approval Process: CanaQuest is positioned to submit New Drug Applications (NDAs) to Health Canada and the US FDA for Phase II/III clinical trials. Approval is projected to take approximately 2 years in Canada and 3 years in the US. The company acknowledges the inherent risks and uncertainties involved in the regulatory approval process, including regulatory requirements, clinical trial outcomes, and potential unforeseen challenges.
Partnerships: CanaQuest has established partnerships with Neeka Health for clinical trial expertise and the NHL Alumni Association for clinical studies. These partnerships will investigate the potential applications of CQ-001 across various indications, paving the way for future clinical trials.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
We welcome having an opportunity to discuss collaboration opportunities.
Please feel free to contact the CEO of CanaQuest directly using the contact info below:
Paul Ramsay, CEO
CanaQuest Medical Corp
paul@canaquest.com
cell: 416-704-3040